NewsMarkets

Business

Eli Lilly Partners With China's InnoCare on Up to $3.35 Billion Drug Deal

The US pharmaceutical giant will pay a $100 million upfront fee to collaborate with the Beijing-based biotech firm on five undisclosed drug targets.

2 publishers · 3 articles · first seen 24 Sept 2026 · updated 2h ago

Markets on this story

  • Kalshi Eli Lilly 7% $0 24hends 1 Jan 2027

    Does the market have this right?

    Wrong market?

How the odds moved · Eli Lilly
0%50%100%7%24 Sept, 05:29 UTCnowSouth China Morning Post: China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts · 26 Sept, 01:00 UTCQuartz: Eli Lilly is partnering with China's InnoCare on a drug deal worth up to $3.35 billion · 24 Sept, 17:20 UTCQuartz: Eli Lilly kooperiert mit Chinas InnoCare bei einem Medikamentenabkommen im Wert von bis zu 3,35 Milliarden US-Dollar. · 24 Sept, 17:20 UTC

Each tick is a source publishing on this story

Price data
TimeChance of yes
now7%
24 Sept, 05:29 UTC7%

Your call. How does this end?

Free, no money involved. Calls are scored against the market's price when you make them, so backing an underdog that wins scores most. Leaderboard · Your calls

Email me when the odds move

We email a link to confirm first. At most one alert email every six hours; unsubscribe in one click. Privacy

How it unfolded

Every source in the order it published, with the odds on Eli Lilly at that moment. A dash means the source published before we started tracking prices.

  1. QuartzEli Lilly is partnering with China's InnoCare on a drug deal worth up to $3.35 billion7%
  2. QuartzEli Lilly kooperiert mit Chinas InnoCare bei einem Medikamentenabkommen im Wert von bis zu 3,35 Milliarden US-Dollar.7%
  3. South China Morning PostChina’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts7%
  4. Current odds7%

Sources

Every article we clustered into this story. Headlines link to the publisher.

  1. China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts South China Morning Post
  2. Eli Lilly is partnering with China's InnoCare on a drug deal worth up to $3.35 billion Quartz
  3. Eli Lilly kooperiert mit Chinas InnoCare bei einem Medikamentenabkommen im Wert von bis zu 3,35 Milliarden US-Dollar. Quartz

In this story

Related stories